is tirzepatide patented Republican Administration Maintains Exclusivity Stance in GLP-1 (Tirzepatide) Compounding Dispute Oral tirzepatide does not effectively

The common injection sites are the abdomen (stomach), the front of the thigh, or the upper arm

A Review in Nature Reviews Endocrinology discusses why patients discontinue GLP-1 receptor agonists and tirzepatide, the metabolic and cardiovascular effects of this discontinuation, and the need for additional research on how to manage the cessation of these drugs

Tirzepatide, also known as Zepbound for weight loss, is a unique dual GLP-1/GIP receptor agonist that stands out in the field of obesity treatments

These may include nausea, vomiting, diarrhea, and stomach pain

Switching from high-fat diet to normal diet ameliorate BTB integrity and improve fertility potential in obese male mice